The price of Syros Pharmaceuticals Inc (NASDAQ:SYRS) shares last traded on Wall Street fell -8.15% to $0.23.
SYRS stock price is now -76.80% away from the 50-day moving average and -93.37% away from the 200-day moving average. The market capitalization of the company currently stands at $5.67M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target enhanced from $11 to $15, H.C. Wainwright Upgraded its rating from Neutral to Buy for Syros Pharmaceuticals Inc (NASDAQ: SYRS). On September 22, 2020, Alliance Global Partners recently initiated its ‘Buy’ rating on the stock quoting a target price of $18, while ‘Wedbush’ rates the stock as ‘Neutral’
In other news, AKKARAJU SRINIVAS, Director bought 9,333 shares of the company’s stock on Dec 30 ’24. The stock was bought for $2,306 at an average price of $0.25. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 27 ’24, Affiliate Flagship Pioneering Fund VII, bought 1,331,624 shares of the business’s stock. A total of $279,641 was incurred on buying the stock at an average price of $0.21. A total of 35.03% of the company’s stock is owned by insiders.
During the past 12 months, Syros Pharmaceuticals Inc has had a low of $0.18 and a high of $8.17. The fifty day moving average price for SYRS is $0.99046 and a two-hundred day moving average price translates $3.464065 for the stock.
The latest earnings results from Syros Pharmaceuticals Inc (NASDAQ: SYRS) was released for 2024-09-30. The net profit margin was -25340.67% and return on equity was -776.96% for SYRS.
